Aenitis Technologies, a Paris, France-based developer of new medical equipment based on acoustic manipulation of biological particles, received €4m in funding.
The funding came from the SME Instrument Phase 2 European program, part of Horizon 2020, in the “Healthcare Biotechnology” category.
The financing will enable the company accelerate the industrial development of its solutions.
Led by Emmanuel Vincent, CEO and co-founder, Aenitis Technologies
Created in July 2014 from the work of Mauricio Hoyos and Jean-Luc Aider, Aenitis Technologies focuses on medical devices’ area, developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies.